The stock of Concordia International Corp (NASDAQ:CXRX) is a huge mover today! About 244,409 shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 86.76% since March 9, 2016 and is downtrending. It has underperformed by 94.17% the S&P500.
The move comes after 9 months positive chart setup for the $219.88 million company. It was reported on Oct, 12 by Barchart.com. We have $7.67 PT which if reached, will make NASDAQ:CXRX worth $167.11 million more.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on November, 10. They expect $1.35 earnings per share, up 3.05% or $0.04 from last year’s $1.31 per share. CXRX’s profit will be $68.08M for 0.81 P/E if the $1.35 EPS becomes a reality. After $1.21 actual earnings per share reported by Concordia International Corp for the previous quarter, Wall Street now forecasts 11.57% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of Concordia International Corp (NASDAQ:CXRX) has “Sector Outperform” rating given on Friday, October 16 by Scotia Capital. On Monday, November 30 the stock rating was initiated by IBC with “Sector Perform”. The rating was maintained by Scotia Capital with “Sector Outperform” on Tuesday, September 29. The rating was downgraded by IBC on Monday, August 15 to “Underperformer”. Goldman Sachs maintained the shares of CXRX in a report on Monday, August 15 with “Neutral” rating. Mackie upgraded Concordia International Corp (NASDAQ:CXRX) on Monday, October 19 to “Speculative Buy” rating. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Outperform” rating by RBC Capital Markets on Thursday, October 1. The firm has “Hold” rating given on Monday, August 15 by GMP Securities. The stock has “Buy” rating given by Laurentian on Tuesday, March 29. The stock has “Hold” rating given by TD Securities on Thursday, August 4.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More notable recent Concordia International Corp (NASDAQ:CXRX) news were published by: Business.Financialpost.com which released: “Concordia International Corp takeover unlikely â€“ Goldman” on September 27, 2016, also Fool.ca with their article: “Concordia International Corp.: A Safe Buy?” published on October 10, 2016, Business.Financialpost.com published: “Concordia International Corp stock crashes on proposed U.K. legislation over …” on September 16, 2016. More interesting news about Concordia International Corp (NASDAQ:CXRX) were released by: Globenewswire.com and their article: “DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Concordia …” published on September 29, 2016 as well as Moodys.com‘s news article titled: “Moody’s assigns B1 to Concordia’s new secured notes; outlook to negative” with publication date: October 06, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.